Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noémi Kéri has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Ibolya Czegle

    Department of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary

    2 shared publications
  • Kinga Komka

    Department of Chemical and Environmental Process Engineering, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, H-1111 Budapest, Hungary

    2 shared publications
  • András Gelley

    Department of Internal Medicine, Gastroenterology and Endocrinology, Buda Hospital of the Hospitaller Order of Saint John of God, Hungary

    1 shared publication
  • András Gelley

    Center of Internal Medicine, Buda Hospital of the Hospitaller Order of Saint John of God, 1023 Budapest, Hungary

    1 shared publication
  • Dóra Szeli

    Department of Internal Medicine, Gastroenterology and Endocrinology, Buda Hospital of the Hospitaller Order of Saint John of God, Hungary

    1 shared publication
  • Dóra Szeli

    Department of Internal Medicine, Gastroenterology and Endocrinology, Buda Hospital of the Hospitaller Order of Saint John of God, H-1027 Budapest, Hungary

    1 shared publication

Latest Publications

  • Open Access

    Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) to Helicobacter pylori Eradication Protocols in a Clarithromycin Resistant and Tetracycline/Bismuth Naive Area: A Real-World Data Retrospective Analysis of 402 Cases (2016–24) in a Single Gastroenterology Unit

    by András Gelley, Noémi Kéri, Péter Birinyi, Kinga Komka, Vajk Hardy, László Döngölő, Dóra Szeli, Ibolya Czegle

    Background: The official current guideline for Helicobacter pylori (H. pylori) eradication is to use tetracycline–bismuth-based protocols as first line treatment due to the increasing incidence of clarithromycin resistance in the last decade. The unavailability of tetracycline and bismuth-containing medicines, however, is an issue in many countries, limiting the routine use of these protocols. The value of using additional probiotics in eradication protocols is also unclear. Direct comparison data on the effect of available bismuth compounds and different probiotic strains on eradication outcome are limited. Goal: The aim of our investigation was to find optimal eradication protocols, supplementations and treatment duration for routine clinical use in our gastroenterology unit, located in a highly clarithromycin-resistant and tetracycline–bismuth-naïve area. Materials and Methods: We conducted a retrospective real-world data analysis of 402 H. pylori positive patients between 2016 and 2024. H. pylori infection was diagnosed using histological examination of gastroscopy samples obtained from the gastric antrum. For the evaluation of treatment success or failure, 14C breath tests and stool H. pylori antigen tests were performed. Data on patient characteristics and treatment protocols were collected from our electronic patient record system, and treatment success was compared between the different treatment regimes. Results: Despite the regional clarithromycin resistance, supplementing clarithromycin-based regimens with bismuth and probiotic during the 14-day treatment duration showed a high and comparable cure rate when compared to tetracycline-based regimens, which are the current first-line therapies. When tetracycline-based combination is available, it is recommended to use it with an additional probiotic to achieve the best possible outcome. Comparison of the effect of available bismuth preparations on treatment success showed no significant difference. Generally, probiotic-containing protocols are more successful, compared to those treatments without this supplement. There was no statistical difference in the cure rates amongst the four probiotic strains used, where sample size allowed statistical analysis. Furthermore, supplementation with probiotics Lactobacillus reuteri ATCC PTA 6475 or Lactobacillus reuteri Protectis® DSM 17938 showed promising high treatment success rates (85.2% and 100.0%, respectively) in our study.


  • Open Access

    Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) to Helicobacter pylori Eradication Protocols in a Clarithromycin Resistant and Tetracycline/Bismuth Naive Area: A Real-World Data Retrospective Analys of 402 Cases (2016-24) in a Single Gastroenterology Unit

    by András Gelley, Noémi Kéri, Péter Birinyi, Kinga Komka, Vajk Hardy, László Döngölő, Dóra Szeli, Ibolya Czegle

    Background: The society guidelines for Helicobacter pylori (H. pylori) eradication, due to the increasing incidence of clarithromycin resistance in the last decade turned to rec-ommend the use tetracycline-bismuth-based protocols as first line treatment. The availability of tetracycline and bismuth containing medicines raising an issue in many countries, limiting the routine use of these protocols. Literature search showed une-quivocal information about the additional value of probiotics to eradication protocols. Direct comparison data of the effect of available bismuth compounds and different probiotic strains on eradication outcome are limited. Goal: The aim of our investigation was to find the optimal eradication protocols, sup-plementations and treatment duration for routine clinical use in our gastroenterology unit in a highly clarithromycin resistant and tetracycline-bismuth-naïve area. Materials and methods: We conducted a retrospective real-world data analysis of 402 cases between 2016-24. H. pylori infection was proved by histological examination of samples obtained from the antrum by gastroscopy, for the evaluation of treatment success or failure, 14C breath tests and stool H. pylori antigen tests were performed. Results: Despite regional clarithromycin resistance pattern, supplementation of the basic clarithromycin-based protocol with bismuth and probiotic in a treatment dura-tion of 14 days, lead to high and comparable success rates to the recommended first line tetracycline-based regimens. When tetracycline-based combination is available, it is recommended to use it with additional probiotic to achieve the best possible out-come. Comparison of the effect of available bismuth preparations on treatment success showed no significant difference. Generally, probiotic containing protocols are more successful, comparing to those treatments that not containing this supplement. No sta-tistical difference was found between the positive effect on success rates of those four probiotic strain, where sample size allowed statistical analysis. A promising result of two case series supplemented with a distinct probiotic combination (Lactobacillus reu-teri ATCC PTA 6475, Lactobacillus reuteri Protectis® DSM 17938) were found with 85.2% and 100.0% success rates.